A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor

Nat Biomed Eng. 2023 Sep;7(9):1063-1080. doi: 10.1038/s41551-023-01013-5. Epub 2023 Apr 17.

Abstract

Vectors that facilitate the engineering of T cells that can better harness endogenous immunity and overcome suppressive barriers in the tumour microenvironment would help improve the safety and efficacy of T-cell therapies for more patients. Here we report the design, production and applicability, in T-cell engineering, of a lentiviral vector leveraging an antisense configuration and comprising a promoter driving the constitutive expression of a tumour-directed receptor and a second promoter enabling the efficient activation-inducible expression of a genetic payload. The vector allows for the delivery of a variety of genes to human T cells, as we show for interleukin-2 and a microRNA-based short hairpin RNA for the knockdown of the gene coding for haematopoietic progenitor kinase 1, a negative regulator of T-cell-receptor signalling. We also show that a gene encoded under an activation-inducible promoter is specifically expressed by tumour-redirected T cells on encountering a target antigen in the tumour microenvironment. The single two-gene-encoding vector can be produced at high titres under an optimized protocol adaptable to good manufacturing practices.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lentivirus* / genetics
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Promoter Regions, Genetic / genetics
  • T-Lymphocytes
  • Transgenes / genetics
  • Tumor Microenvironment